PubMedRandomized Controlled TrialHuman Subjects

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver Heidi J, Olson Dianna, Mayfield Dustin, Wright Patricia, Nian Hui, Mashayekhi Mona, Koethe John R, Niswender Kevin D, Luther James M, Brown Nancy J

Diabetes, obesity & metabolism2023DOI: 10.1111/dom.15113

glucagon-like peptide-1 receptor agonistliraglutide

Quality Score

7/10

Citations

Subjects

Human

PeptideVault Analysis

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for glucagon-like peptide-1 receptor agonist, liraglutide are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the sample size is modest, which limits statistical power and the ability to detect smaller but clinically meaningful effects. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for glucagon-like peptide-1 receptor agonist, liraglutide. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Key Findings

The study found that caloric restriction led to greater weight loss and more favorable improvements in body composition compared to liraglutide treatment alone for adults with obesity and prediabetes. Caloric restriction also showed a spontaneous reduction in dietary simple carbohydrates, leading to improved insulin resistance scores.

Limitations

The sample size was relatively small (88 participants), which may limit the generalizability of the findings. Additionally, the study duration was only 14 weeks, so long-term effects are not addressed.

PeptideVault Analysis

Highlighting the comparative efficacy of caloric restriction versus liraglutide treatment in managing obesity and prediabetes, emphasizing the importance of personalized intervention strategies.

glucagon-like peptide-1 receptor agonistliraglutide

Caloric Restriction Outperforms Liraglutide in Weight Loss and Body Composition Improvement for Prediabetes Patients

Published: May 17, 2026 | Source: Diabetes, obesity & metabolism (2023) | Category: glucagon-like peptide-1 receptor agonist, liraglutide

Overview

A recent study published in Diabetes, Obesity & Metabolism compared the effects of caloric restriction and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide on weight loss and body composition improvement among adults with obesity and prediabetes. The findings suggest that while both methods are beneficial for cardiometabolic risk reduction, caloric restriction leads to greater weight loss and more favorable changes in body fat distribution.

Study Background

Previous research has highlighted the benefits of GLP-1RAs like liraglutide in managing type 2 diabetes and obesity. However, questions remain about their comparative efficacy against traditional dietary interventions such as caloric restriction. This study aimed to address these gaps by comparing weight loss outcomes between caloric restriction and liraglutide treatment.

What the Research Found

The randomized trial involved 88 adults with obesity and prediabetes who were assigned to one of three groups: caloric restriction (-390 kcal/day), liraglutide (1.8 mg/day), or sitagliptin (a DPP-4 inhibitor used as a control). After 14 weeks, the study found that:

Weight Loss: Caloric restriction led to weight loss in 44% of participants, compared to 22% for liraglutide and only 5% for sitagliptin.
Body Composition: The ratio of fat to lean mass decreased by 6.5% with caloric restriction versus 2.2% with liraglutide, while there was no change in the sitagliptin group.
Visceral Fat Reduction: Caloric restriction resulted in a 9.5% reduction in visceral fat compared to 4.8% for liraglutide and none for sitagliptin.

Additionally, spontaneous dietary changes in the caloric restriction group led to improved insulin resistance scores (HOMA-IR).

What This Means for Peptide Users

For individuals with obesity and prediabetes, this study highlights that while GLP-1RAs like liraglutide offer significant benefits, caloric restriction may be more effective in promoting weight loss and improving body composition. However, the choice of intervention should consider individual preferences and risk factors.

Limitations and Caveats

The study's small sample size (88 participants) limits its generalizability to broader populations. Additionally, the short duration (14 weeks) means long-term effects remain uncertain. These limitations underscore the need for further research to confirm these findings in larger and more diverse groups over extended periods.

How This Compares to Previous Research

While previous studies have shown positive outcomes with GLP-1RAs like liraglutide, this study provides a direct comparison against caloric restriction. Other research has also indicated the benefits of dietary interventions for improving metabolic health, aligning with these findings but emphasizing the need for personalized approaches.

Our Analysis

PeptideVault views this study as valuable in providing evidence-based insights into weight management strategies for prediabetes patients. The comparative analysis offers a nuanced understanding of how different treatments can impact body composition and cardiometabolic risk factors differently. However, the limitations noted highlight the importance of cautious interpretation until further validation is achieved.

Key Takeaways

Caloric Restriction Outperforms: Caloric restriction leads to greater weight loss and more favorable changes in body fat distribution compared to liraglutide.
Personalized Interventions: The study supports a personalized approach to treatment, considering individual preferences and risk factors for optimal outcomes.
Further Research Needed: Larger studies over longer durations are required to confirm these findings and explore long-term effects.

Original Source

Citation: Silver Heidi J, Olson Dianna, Mayfield Dustin et al. (2023). Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.. Diabetes, obesity & metabolism. DOI: 10.1111/dom.15113

Access: https://pubmed.ncbi.nlm.nih.gov/37188932/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on glucagon-like peptide-1 receptor agonist, explore our research guides.

Citation

Silver Heidi J, Olson Dianna, Mayfield Dustin et al.. (2023). Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.15113

View full text on PubMed

Related Papers

Medications for Obesity: A Review.

Gudzune Kimberly A et al. · JAMA · 2024

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

Thomsen Reimar W et al. · Diabetes, obesity & metabolism · 2025

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al. · Drug design, development and therapy · 2025

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Khavinson Vladimir et al. · Cells · 2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M et al. · JAMA · 2022

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.